MBG453
MBG453 is a pharmaceutical drug with 10 clinical trials. Currently 1 active trials ongoing. Historical success rate of 12.5%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
6
Early Stage
4
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
11.1%
1 of 9 finished
88.9%
8 ended early
1
trials recruiting
10
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM
MBG453 in Lower Risk MDS
A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy
A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).
STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS
Clinical Trials (10)
Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM
MBG453 in Lower Risk MDS
A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy
A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).
STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS
HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS
Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Study of Select Combinations in Adults With Myelofibrosis
All 10 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 10